Treatments for gout and chronic kidney diseases

Arthrosi Therapeutics is focused on developing innovative therapies for gout and chronic kidney disease, with its lead compound, AR882, showing significant promise in clinical trials. AR882 is a potent uricosuric drug that has demonstrated the ability to lower serum urate (sUA) levels effectively in gout patients. In a Phase 2a study, AR882 achieved remarkable results, with 93% of patients reducing their sUA levels to below 5 mg/dL, a stark contrast to the lower efficacy rates of existing treatments like allopurinol and febuxostat. This high potency positions AR882 as a potential game-changer in gout management, particularly for patients who are intolerant to or do not respond adequately to current therapies.

The company is advancing AR882 through various clinical trials, including pivotal Phase 3 studies aimed at evaluating its efficacy and safety in a broader patient population. Arthrosi Therapeutics emphasizes a patient-centered approach, aiming to improve the quality of life for individuals suffering from gout and related conditions. Their commitment to rigorous clinical evaluation ensures that any new treatments will be thoroughly assessed for safety and effectiveness, aligning with regulatory standards for drug approval. Through these efforts, Arthrosi Therapeutics seeks to address the unmet needs of the millions of gout patients who currently experience inadequate treatment options.

United States

Arthrosi Therapeutics is a leading clinical-stage biotech company dedicated to advancing therapies for gout disease. Our proprietary oral drug candidate, AR882 which is currently in clinical Phase 3, has demonstrated unprecedented sustained urate lowering in gout patients and reduction of tophi, showing exceptional potential to treat millions of patients suffering from gout and tophaceous gout. At Arthrosi Therapeutics, we are committed to transforming the treatment landscape and improving the lives of patients worldwide.

Arthrosi Therapeutics

Company Details